CNTA vs. LQDA, INVA, MGNX, SAVA, TYRA, IMNM, OCUL, ABVX, SPRY, and ARQT
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Liquidia (LQDA), Innoviva (INVA), MacroGenics (MGNX), Cassava Sciences (SAVA), Tyra Biosciences (TYRA), Immunome (IMNM), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Centessa Pharmaceuticals (NASDAQ:CNTA) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
In the previous week, Liquidia had 10 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 21 mentions for Liquidia and 11 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.05 beat Liquidia's score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.
82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 31.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Liquidia's net margin of -674.42%. Centessa Pharmaceuticals' return on equity of -56.07% beat Liquidia's return on equity.
Centessa Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 12.74%. Liquidia has a consensus target price of $21.00, suggesting a potential upside of 65.22%. Given Liquidia's higher probable upside, analysts clearly believe Liquidia is more favorable than Centessa Pharmaceuticals.
Liquidia has higher revenue and earnings than Centessa Pharmaceuticals. Liquidia is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Centessa Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Liquidia received 165 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 66.55% of users gave Liquidia an outperform vote while only 48.78% of users gave Centessa Pharmaceuticals an outperform vote.
Summary
Centessa Pharmaceuticals beats Liquidia on 11 of the 18 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
